NIMBEX® (cisatracurium besylate)

grdientline
A Nondepolarizing Neuromuscular Blocking (NMB) Agent
nimbex-200-mob
nimbex-20-mob
nimbex-10-mob

An appropriate choice for your patients requiring an NMB1

     

  • Intermediate onset and duration of action
  • Severe anaphylactic reactions to NIMBEX have been reported
  • NIMBEX has been associated with residual paralysis; patients with neuromuscular disease and carcinomatosis may be at higher risk
  • Patients with renal or hepatic impairment receiving extended administration of NIMBEX may be at higher risk of seizures
  • AEs <1%: bradycardia, hypotension, flushing, bronchospasm, and/or rash
  •